PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative cost of revenue growth (cost reduction) can be positive but verify quality impact. Benjamin Graham would examine if cost cuts are sustainable.
100.00%
Gross profit growth above 25% indicates exceptional core profitability improvement. Warren Buffett would verify pricing power and cost control.
No Data
No Data available this quarter, please select a different quarter.
10.75%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
-21.32%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.47%
Operating expenses growth 0-5% reflects moderate increase. Benjamin Graham would check revenue alignment.
1.47%
Total costs growth 0-3% reflects moderate increase. Benjamin Graham would check revenue alignment.
No Data
No Data available this quarter, please select a different quarter.
6.88%
D&A growth 5-10% suggests significant asset additions. Howard Marks would investigate investment returns.
-1.39%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-1.47%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-3.00%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-1.89%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.89%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
2.63%
EPS growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
2.63%
Diluted EPS growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
3.22%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
3.22%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.